R&D Sponsored The importance of time: Grifols seeks biomarkers for early d... Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J.
News Grifols gets $21m award for Parkinson's biomarker hunt Grifols has been awarded a $21m grant from the Michael J Fox Foundation to find plasma biomarkers to predict Parkinson's years before symptoms start.
News Bayer gains ground in two-fronted Parkinson's offensive Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.
News Roche's Parkinson's hope fails second clinical trial Roche and Prothena's alpha-synuclein-targeting prasinezumab for Parkinson's fails again, leaving them sifting through the data for efficacy signals.
News AbbVie gets continuous Parkinson's drug over the line in US AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data.
News MeiraGTx plans to take Parkinson's gene therapy into phase 3 Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial.
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.